MedTrace Logo

Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention

NCT06626126 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1448

Last updated 2024-10-16

No results posted yet for this study

Summary

This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.

Conditions

  • Coronary Arterial Disease (CAD)
  • Percutaneous Coronary Intervention
  • LDL-cholesterol
  • Lipid Metabolism Disorders

Interventions

OTHER

ApoB-guided-LLT

Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets

OTHER

LDL-C-guided-LLT

Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.

Sponsors & Collaborators

  • University of Medicine and Pharmacy at Ho Chi Minh City

    collaborator OTHER

  • University Medical Center Ho Chi Minh City (UMC)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2028-01-01
Completion
2029-01-01

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06626126 on ClinicalTrials.gov